China issues 15th Five-Year Plan targeting 20% annual growth for innovative drugs by 2030
On September 18, ten Chinese ministries jointly issued the 15th Five-Year Plan for the pharmaceutical industry, setting 2030 targets including operating revenue exceeding 3.5 trillion yuan for above-scale enterprises, over 20% annual growth for innovative drugs, and at least five products with global sales exceeding $1 billion. The plan outlines 25 tasks across eight areas, emphasizing original innovation, first-in-class drugs, and frontier technologies like AI and gene editing.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Reporting timeline
Ten Chinese Ministries Release Pharma Plan, Boosting Innovative Drug Stocks
On September 18, the innovative drug sector in China saw a significant surge, with stocks like Nanhua Biotech hitting daily limits, following the joint release of the '15th Five-Year Plan for the Development of the Pharmaceutical Industry' by ten government departments including MIIT and NDRC. The Plan sets ambitious targets for 2030, aiming to keep China's biopharmaceutical R&D at the global forefront and achieve breakthroughs in key core technologies. It outlines indicative goals for the 15th Five-Year Plan period, including operating revenues for above-scale pharmaceutical enterprises exceeding 3.5 trillion yuan, an average annual growth rate of over 20% for the innovative drug industry, and more than five products achieving global annual sales exceeding USD 1 billion. Additionally, it targets an average R&D investment intensity of over 10% for listed pharmaceutical firms, a global first-in-class (FIC) innovative drug share exceeding 25%, and over 200 innovative medical devices receiving market approval. The Plan also aims for 50 pharmaceutical enterprises with annual revenues over 10 billion yuan and 20 pharmaceutical parks with output value exceeding 100 billion yuan.
Read sourceChina's 15th Five-Year Plan Targets 20% Annual Growth for Innovative Drug Sector
On September 18, ten Chinese government departments, including the Ministry of Industry and Information Technology (MIIT) and the National Development and Reform Commission, jointly issued the '15th Five-Year Plan for the Development of the Pharmaceutical Industry.' The plan sets ambitious targets for 2030, including operating revenue for above-scale pharmaceutical industrial enterprises exceeding RMB 3.5 trillion and an average annual growth rate of over 20% for the innovative drug sector (886015). It aims for China's biopharmaceutical R&D and application to remain globally leading, with the number of approved innovative drugs ranking among the world's highest and at least five products achieving global annual sales exceeding USD 1 billion. The plan outlines 25 key tasks across eight areas, emphasizing enhanced original innovation capabilities, support for first-in-class (FIC) and best-in-class (BIC) drugs, and the deployment of frontier technologies such as AI, quantum computing, and gene editing. The MIIT stated it will coordinate implementation to ensure tangible results.
Read sourceChina's 15th Five-Year Plan Backs First-in-Class and Best-in-Class Drug Development
On September 18, China's Ministry of Industry and Information Technology (MIIT), the National Development and Reform Commission (NDRC), and eight other departments jointly released the '15th Five-Year Plan for the Development of the Pharmaceutical Industry.' The plan aims to enhance original innovation capabilities by focusing on key areas such as major infectious diseases, chronic diseases, rare diseases, and pediatric medications. It seeks to strengthen the role of enterprises as primary innovators and accelerate the upgrade of China's R&D in innovative drugs and medical devices toward first-in-class, breakthrough, and disruptive innovations. Specifically, the plan supports pharmaceutical industrial enterprises in targeting cutting-edge medical technologies to develop a batch of First-in-Class (FIC) and Best-in-Class (BIC) drugs with new targets, new mechanisms, and new drug types. It also calls for accelerating the R&D and application of advanced, leading-edge high-end medical devices.
Read sourceShow 4 older updatesHide older updates
China Issues 15th Five-Year Plan for Pharmaceutical Industry, Targets 3.5 Trillion Yuan Revenue
On September 18, China's Ministry of Industry and Information Technology (MIIT), the National Development and Reform Commission (NDRC), and eight other departments jointly released the '15th Five-Year Plan for the Development of the Pharmaceutical Industry.' The plan sets a target for above-scale pharmaceutical industrial enterprises to achieve operating revenue exceeding 3.5 trillion yuan by 2030. Key forward-looking indicators include an average annual growth rate of over 20% for the innovative drug sector, more than five products with global annual sales exceeding $1 billion, 50 pharmaceutical enterprises with annual revenues surpassing 10 billion yuan, and 20 pharmaceutical industrial parks at the hundred-billion-yuan level. For innovation-driven development, the plan targets an average annual R&D investment intensity of over 10% for listed pharmaceutical companies and a share of first-in-class new drugs accounting for more than 25% of the global total. The plan focuses on industrial scale and efficiency, innovation, enterprise cultivation, and cluster development.
China's 15th Five-Year Plan Targets 20% Annual Growth for Innovative Drug Industry
On September 18, ten Chinese government departments, including the Ministry of Industry and Information Technology and the National Development and Reform Commission, jointly released the '15th Five-Year Plan for the Development of the Pharmaceutical Industry.' The plan sets development goals through 2030, aiming to keep China's biopharmaceutical R&D and application at the global forefront, achieve systematic breakthroughs in key core technologies, and accelerate the transformation of the biopharmaceutical industry into a new pillar of the national economy. It proposes ten expected indicators, including that operating revenue of pharmaceutical enterprises above designated size will exceed 3.5 trillion yuan, the innovative drug industry will achieve an average annual growth rate of over 20%, and more than five products will achieve global annual sales exceeding USD 1 billion. Other targets include R&D investment intensity of listed pharmaceutical companies reaching over 10%, the proportion of first-in-class drugs globally exceeding 25%, approval of more than 200 innovative medical devices, 50 pharmaceutical enterprises with annual revenue exceeding 10 billion yuan, and 20 hundred-billion-yuan-level pharmaceutical industrial parks.
Read sourceChina Issues 15th Five-Year Plan for Pharma Industry, Targets 20% Annual Growth for Innovative Drugs
On September 18, ten Chinese government departments jointly issued the '15th Five-Year Plan for the Development of the Pharmaceutical Industry,' setting ambitious goals through 2030. The plan targets an average annual growth rate of over 20% for the innovative drug industry and aims for operating revenue of above-scale pharmaceutical enterprises to exceed 3.5 trillion yuan. It also seeks to have more than five products achieve global annual sales exceeding $1 billion, 50 pharmaceutical enterprises with revenue over 10 billion yuan, and 20 pharmaceutical industrial parks with revenues exceeding 100 billion yuan. The plan focuses on eight key areas including innovation-driven development, digital transformation, and precision diagnosis, proposing 25 key tasks. Experts cited in the article, including Li Yan from the State Council's Development Research Center, view the 15th Five-Year period as critical for China's biomedical industry to transition from quantitative to qualitative change. Li Yan noted that while China has made substantial progress, with 76 innovative drugs approved in 2025 and 33.7% of global clinical-stage pipelines, significant shortcomings remain in original innovation, with most projects focused on follow-on incremental innovations rather than First-in-Class drugs.
Read sourceChina Issues 15th Five-Year Plan for Pharmaceutical Industry, Targets 20% Annual Growth for Innovative Drugs
On September 18, ten Chinese ministries including the Ministry of Industry and Information Technology (MIIT) and the National Development and Reform Commission (NDRC) jointly issued the '15th Five-Year Plan for the Development of the Pharmaceutical Industry.' The plan sets ambitious targets for 2030, including operating revenue exceeding 3.5 trillion yuan for above-scale pharmaceutical enterprises, an average annual growth rate of over 20% for the innovative drug sector, and at least five products with global annual sales exceeding USD 1 billion. It also aims for the number of approved innovative drugs to rank among world leaders and for first-in-class (FIC) innovative drugs to account for over 25% globally. The plan outlines 25 key tasks across eight areas, focusing on enhancing original innovation capabilities, supporting the development of first-in-class and best-in-class drugs, and accelerating R&D in frontier technologies such as AI, quantum computing, gene editing, and brain-computer interfaces. The MIIT stated it will coordinate implementation across multiple policy areas including regulation, pricing, healthcare, and talent.
Read source